

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 October 2021 (07.10.2021)



(10) International Publication Number
WO 2021/198116 A1

(51) International Patent Classification:

A61K 9/00 (2006.01)	A61P 31/14 (2006.01)
A61K 9/08 (2006.01)	A61P 31/16 (2006.01)
A61K 31/609 (2006.01)	A61P 11/00 (2006.01)
A61K 47/40 (2006.01)	A61P 11/06 (2006.01)
A61P 31/00 (2006.01)	A61P 27/02 (2006.01)
A61P 31/04 (2006.01)	

(21) International Application Number:

PCT/EP2021/058047

(22) International Filing Date:

26 March 2021 (26.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2004844.3	01 April 2020 (01.04.2020)	GB
2005340.1	09 April 2020 (09.04.2020)	GB
2010573.0	09 July 2020 (09.07.2020)	GB
2016274.9	14 October 2020 (14.10.2020)	GB
2103970.6	22 March 2021 (22.03.2021)	GB

(71) Applicant: UNION THERAPEUTICS A/S [DK/DK];
Tuborg, Havnevej 18, 2900 Hellerup (DK).

(72) Inventors: SOMMER, Morten; c/o UNION therapeutics A/S Tuborg, Havnevej 18, 2900 Hellerup (DK). TOFT-KEHLER, Rasmus; c/o UNION therapeutics A/S Tuborg, Havnevej 18, 2900 Hellerup (DK). TOFT-KEHLER, Anne, Katrine; c/o UNION therapeutics A/S Tuborg, Havnevej 18, 2900 Hellerup (DK). DITZINGER, Günter; c/o UNION therapeutics A/S Tuborg, Havnevej 18, 2900 Hellerup (DK). JELLINGSOE, Mads; c/o UNION therapeutics A/S Tuborg, Havnevej 18, 2900 Hellerup (DK). ANDRES, Philippe; c/o UNION therapeutics A/S Tuborg, Havnevej 18, 2900 Hellerup (DK). KNOPP, Matthias, Manne; c/o UNION therapeutics A/S Tuborg, Havnevej 18, 2900 Hellerup (DK).


(74) Agent: HGF; 1 City Walk, Leeds West Yorkshire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: FORMULATION

Figure 1

A



(57) Abstract: The invention relates to formulations comprising a halogenated salicylanilide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. The formulations may be in the form of a liquid formulation, particularly an aqueous formulation, and provide high concentrations of solubilised halogenated salicylanilide. Also disclosed a formulations in the form of powders and aerosols. Also disclosed are the formulations for use in the treatment of bacterial and viral infections, and the treatment of inflammatory diseases. The formulations are particularly suitable for administration by inhalation for the treatment of bacterial and viral pulmonary infections and the treatment of pulmonary inflammatory diseases.

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*